ReviewBiomedicines2019
The Potential of the Cyclotide Scaffold for Drug Development.
Review in Biomedicines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 58 citations in OpenAlex.
- Cyclotides from Plants Driving the Next Generation of Antibacterial Agents.Antibiotics (Basel, Switzerland) · 2026Review
- Computational screening of AI-derived cyclotides as putative VEGFR2 binders for wound-site angiogenesis.Scientific reports · 2026Article
- Advances in cyclotide research: bioactivity to cyclotide-based therapeutics.Molecular diversity · 2025Review
- Plant Defense Peptides: Exploring the Structure-Function Correlation for Potential Applications in Drug Design and Therapeutics.ACS omega · 2025Review
- Miniprotein engineering for inhibition of PD-1/PD-L1 interaction.Protein science : a publication of the Protein Society · 2024Article
- Resistance is futile: targeting multidrug-resistant bacteria withRSC chemical biology · 2023Review
- Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Native and Engineered Cyclic Disulfide-Rich Peptides as Drug Leads.Molecules (Basel, Switzerland) · 2023Review
- Plant-based production of an orally active cyclotide for the treatment of multiple sclerosis.Transgenic research · 2023Article
- Molecular Peptide Grafting as a Tool to Create Novel Protein Therapeutics.Molecules (Basel, Switzerland) · 2023Review
- Review
- Using the Cyclotide Scaffold for Targeting Biomolecular Interactions in Drug Development.Molecules (Basel, Switzerland) · 2022Review
- A Revised Phylogenetic Classification forPlants (Basel, Switzerland) · 2022Review
- Discovery of the cyclotide caripe 11 as a ligand of the cholecystokinin-2 receptor.Scientific reports · 2022Article
- LC-MS/MS identification and structural characterization of isolated cyclotides from precursor sequences ofJournal of biosciences · 2022Article
- The Updated Review on Plant Peptides and Their Applications in Human Health.International journal of peptide research and therapeutics · 2022Review
- Enabling Efficient Folding and High-Resolution Crystallographic Analysis of Bracelet Cyclotides.Molecules (Basel, Switzerland) · 2021Article
- Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Plant derived cyclic peptides.Biochemical Society transactions · 2021Review
- Isolation and characterization of cyclotides from the leaves of3 Biotech · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cyclotides are a novel class of micro-proteins (≈30-40 residues long) with a unique topology containing a head-to-tail cyclized backbone structure further stabilized by three disulfide bonds that form a cystine knot. This unique molecular framework makes them exceptionally stable to physical, chemical, and biological degradation compared to linear peptides of similar size. The cyclotides are also highly tolerant to sequence variability, aside from the conserved residues forming the cystine knot, and are orally bioavailable and able to cross cellular membranes to modulate intracellular protein-protein interactions (PPIs), both in vitro and in vivo. These unique properties make them ideal scaffolds for many biotechnological applications, including drug discovery. This review provides an overview of the properties of cyclotides and their potential for the development of novel peptide-based therapeutics. The selective disruption of PPIs still remains a very challenging task, as the interacting surfaces are relatively large and flat. The use of the cell-permeable highly constrained polypeptide molecular frameworks, such as the cyclotide scaffold, has shown great promise, as it provides unique pharmacological properties. The use of molecular techniques, such as epitope grafting, and molecular evolution have shown to be highly effective for the selection of bioactive cyclotides. However, despite successes in employing cyclotides to target PPIs, some of the challenges to move them into the clinic still remain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.